NEW YORK, Dec. 24, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
MarketVIEW: Hepatitis C virus vaccines
http://www.reportlinker.com/p01934496/MarketVIEW-Hepatitis-C-virus-vaccines.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Hepatitis C is caused by infection with the Hepatitis C virus (HCV). Transmission is predominately through the blood-to blood route where persons such as current or former injection drug users, past recipients of blood transfusions or solid organ transplants and chronic hemodialysis patients are examples of risk groups. HCV infection becomes chronic in 75-85% of cases and if left untreated can result in chronic liver disease, cirrhosis and hepatocellular carcinoma (HCC). The WHO estimates that about 3% of the world's population has been infected with HCV and that some 170 million are chronic carriers at risk.
This MarketVIEW product contains two comprehensive MS Excel-based models + summary presentation which forecast the potential commercial value of Hepatitis C Virus (HCV) TX and PX vaccines across major Western markets until 2030. The models contain value ($ m) and volume (mio doses) predictions per product type along with timeframe, pricing and penetration estimates for all adult risk groups. The product also includes an in depth review of latest HCV epidemiological trends, developments in new antivirals and immunological based treatments.
THIS PRODUCT IS A EXECUTIVE PRESENTATION + 2 MODELS
Author's note
Executive Summary
Commercial model: major outputs
HCV TX vaccines: revenues ($m) by scenario
HCV TX vaccines: revenues ($m) by region
HCV PX vaccines: revenues ($m) by scenario
HCV PX vaccines: revenues ($m) by region
Chronically infected HCV population (000s), by region, 2010-2030
Treated patients (000s), any antiviral therapy (all genotypes), by region, 2010-2030
Treated patients (000s), any antiviral therapy (genotype 1), by region, 2010-2030
Commercial model: key assumptions
The role of HCV TX vaccine
The role of HCV PX vaccine
Key inputs: TX vaccine
Key inputs: PX vaccine
Overview of modelling strategy: TX vaccine
Pricing: TX vaccine
Overview of modelling strategy: PX vaccine
Pricing: PX vaccine
Epidemiology inputs: HCV prevalence
Epidemiology inputs: HCV populations by genotype
Epidemiology inputs: Estimated HCV populations by genotype, 2010
Epidemiology inputs: Injecting drug users
Epidemiology inputs: Estimated treatment rates (% of chronically infected HCV population)
HCV epidemiology summary
US: epidemiology
Europe: epidemiology
Canada: epidemiology
Japan, South Korea, Australia: epidemiology
HCV genotype distribution
Current HCV treatments – review of latest clinical data
Future HCV therapies
HCV vaccine pipeline
Okairos (TerCvax and ProCvax)
Globeimmune (GI-5005)
ChronTech (ChronVac-C)
Transgene (TG4040)
Further methodology
Bibliography
About VacZine Analytics
Disclaimer
PAGES: ~75 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model TX vaccine (MS Excel-based)
Title sheet CHARTS – VALUE CHARTS – VOLUME CHARTS – Epi Value Volume Epi Country worksheets ? US Canada Australia France Germany Italy Spain UK Other Europe Japan South Korea Australia Source material ? Total population 15-64 yrs population TX vaccine price summary HCV prevalence Genotype (% distribution) Genotype prevalence (number) IDUs Treatment rates HCV cases US HCV cases UK HCV cases Germany HCV cases by risk group Incivek sales Clinical trials Treatment pathway Back page
Worksheets = 40 interconnected
Contents – Vaccine demand model PX vaccine (MS Excel-based)
Title sheet
CHARTS – VALUE
CHARTS – VOLUME
Value
Volume
Epi
Country worksheets ?
US
Canada
Australia
France
Germany
Italy
Spain
UK
Other Europe
Japan
South Korea
Australia
Source material ?
Total population
15-64 yrs population
IDUs
Vaccine price summary
Back page
Worksheets = 40 interconnected
To order this report: MarketVIEW: Hepatitis C virus vaccines http://www.reportlinker.com/p01934496/MarketVIEW-Hepatitis-C-virus-vaccines.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
SOURCE Reportlinker
Share this article